6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A guide to delayed-onset and rare adverse events from Leqvio (inclisiran), including injection-site reactions, muscle symptoms, liver enzyme changes, and long-term safety data from ORION trials and FDA post-market reports.
Injection-site reactions were most common (8.2% vs 1.8% placebo) across ORION-9/10/11. No significant liver, kidney, or muscle toxicity signals emerged.
Injection-site reactions affect about 8.2% of Leqvio users and are usually mild. No withdrawal syndrome exists, but LDL-C rebounds within 6-12 months of stopping.
Most Leqvio side effects are mild injection-site reactions (8.2% vs 1.8% placebo); permanent effects remain unconfirmed in trial data. See what to monitor.
A guide to the rare but serious adverse events linked to Leqvio (inclisiran), covering trial data, FDA labeling, post-market reports, and how to monitor patients on twice-yearly PCSK9i injections.
Leqvio's long-term side effects are mostly mild injection-site reactions (8.2%); serious events match placebo, except in severe renal or hepatic impairment.